Protein Kinase C Signaling Mediates a Program of Cell Cycle Withdrawal in the Intestinal Epithelium

Mark R. Frey, Jennifer A. Clark, Olga Leontieva, Joshua M. Uronis, Adrian R. Black, and Jennifer D. Black

Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York 14263

Abstract. Members of the protein kinase C (PKC) family of signal transduction molecules have been widely implicated in regulation of cell growth and differentiation, although the underlying molecular mechanisms involved remain poorly defined. Using combined in vitro and in vivo intestinal epithelial model systems, we demonstrate that PKC signaling can trigger a coordinated program of molecular events leading to cell cycle withdrawal into G0. PKC activation in the IEC-18 intestinal crypt cell line resulted in rapid downregulation of D-type cyclins and differential induction of p21waf1/cip1 and p27kip1, thus targeting all of the major G1/S cyclin-dependent kinase complexes. These events were associated with coordinated alterations in expression and phosphorylation of the pocket proteins p107, pRb, and p130 that drive cells to exit the cell cycle into G0 as indicated by concomitant downregulation of the DNA licensing factor cdc6. Manipulation of PKC isozyme levels in IEC-18 cells demonstrated that PKCα alone can trigger hallmark events of cell cycle withdrawal in intestinal epithelial cells. Notably, analysis of the developmental control of cell cycle regulatory molecules along the crypt–villus axis revealed that PKCα activation is appropriately positioned within intestinal crypts to trigger this program of cell cycle exit–specific events in situ. Together, these data point to PKCα as a key regulator of cell cycle withdrawal in the intestinal epithelium.

Key words: protein kinase C • cell cycle • intestinal mucosa • pocket proteins • cyclin-dependent kinase regulation

Introduction

Signaling pathways mediated by the protein kinase C (PKC) family of serine-threonine kinases are involved in the regulation of a wide variety of fundamental cellular processes, including cell growth and cell cycle progression, differentiation, and apoptosis (Nishizuka, 1992; Dekker and Parker, 1994; Fishman et al., 1998; Black, 2000). The PKC family consists of at least 10 distinct isozymes (α, βI, βII, γ, δ, ε, η, θ, ζ, and i) which share the same basic structure but differ with respect to activator and cofactor requirements, substrate specificity, tissue expression, and subcellular distribution (Dekker and Parker, 1994). Phylogenetic conservation of individual PKCs and their widespread expression in different cell types underscore the central importance of members of this family in regulation of normal cellular functions. Furthermore, evidence of alterations in the expression/activity of PKC isozymes in neoplastic tissues (e.g., Guillem et al., 1987; Wali et al., 1991; Kahl-Rainer et al., 1996; Verstovsek et al., 1998), together with the identification of PKC as the major cellular receptor for tumor-promoting phorbol esters (e.g., PMA) (Castagna et al., 1982), suggests that disruption of the signaling pathways mediated by these molecules may contribute to uncontrolled cell growth and transformation.

Increasing evidence points to a role for PKC signaling in regulation of progression through the cell cycle, although the underlying molecular mechanisms remain unclear (Fishman et al., 1998; Black, 2000). Control of G0/G1→S phase transit is accomplished primarily through regulation of the phosphorylation state of members of the pocket protein family of growth suppressor proteins, p107, pRb, and p130. In the hypophosphorylated (active) state, these molecules repress the activity of E2F transcription factors, which is required for expression of genes essential for DNA synthesis. In preparation for S phase entry, cyclin–cyclin-
dependent kinase (cdk) complexes (cyclin D–cdk4/6 and cyclin E–cdk2) phosphorylate pRb, p107, and p130, inactivating their growth-suppressive function (Graña and Reddy, 1995). An additional complex, cyclin A–cdk2, is critical for S phase entry/DNA synthesis, and is thought to maintain pocket protein phosphorylation during S phase (Li et al., 1993; Ludlow et al., 1993; Mayol et al., 1995). The activity of cyclin–cdk complexes is in turn regulated by cdk phosphorylation, expression and binding of cyclins, and association of cdk inhibitory proteins (CKIs) such as p21waf1/cip1 and p27kip1 (Cip/Kip family members) and p15 and p16 (Ink4 family members) (Pines, 1995; Chellappan et al., 1998; Sherr and Roberts, 1999). Protein pocket protein has also been linked to regulation of cell cycle exit and onset of differentiation; cell cycle withdrawal into G0 involves coordinated regulation of pocket protein phosphorylation and expression, including hypophosphorylation of p107 and pRb, rapid downregulation of p107, and accumulation of the G0-specific phosphoforms 1 and 2 of p130 (Garriga et al., 1998; Graña et al., 1998). Emerging data from several studies implicate PKC isozyme(s) in either positive or negative regulation of G1-S progression, via alterations in the expression of cyclins and/or cdk inhibitors and modulation of the activity of specific cyclin–cdk complexes (Fishman et al., 1998; Black, 2000).

In an effort to further understand the interplay between PKC signaling and regulation of the cell cycle machinery, our laboratory has used the intestinal epithelium as a model system. The unique architecture of this self-renewing tissue, with its well-defined regions of cell proliferation, differentiation, mature function, and senescence, has enabled correlation of changes in the expression and activation of PKC isozymes with specific stages of development. Using a combined morphological and biochemical approach, we have determined that several PKC isozymes (α, βII, δ, and ζ) are activated precisely at the point within intestinal crypts at which cells cease dividing (Saxon et al., 1994), suggesting that one or more of these molecules are involved in negative regulation of cell growth in this system. Consistent with these findings, direct activation of PKC (α, δ, and ε) in the nontransformed IEC-18 immature intestinal crypt cell line resulted in cell cycle arrest in G0/G1 phase (Frey et al., 1997). Differential downmodulation of individual PKC isozymes indicated that PKCα, in particular, is sufficient to inhibit cell cycle progression in this system. PKC-mediated cell cycle arrest in G0/G1 was shown to involve induction of Cip/Kip family cdk inhibitors and hypophosphorylation/activation of pRb, thus linking PKCα to control of cdk activity and the growth-suppressive function of pRb in the intestinal epithelium.

This study uses in vitro and in vivo model systems to investigate further the cell cycle–specific effects of PKC signaling in intestinal epithelial cells. The data demonstrate for the first time that PKC signaling can initiate a coordinated program of cell cycle withdrawal into G0 and that PKCα is sufficient to initiate this program of cell cycle exit–specific effects. Similar changes in the regulation of cell cycle regulatory molecules were observed coincident with PKC activation in the midcrypt region in situ, underscoring the physiological relevance of these findings. Together, the data implicate members of the PKC family as key regulators of cell cycle withdrawal in the midcrypt region of the intestinal epithelium.

**Materials and Methods**

**Antibodies**

Monoclonal anti–cyclin D1, polyclonal rabbit anti-p15, -p16, -cdk4, -cyclin A, -cyclin E (pan), -cyclin E, -pRb, -p107, -p130, -PKCα, and -PKCε, and polyclonal goat anti-p15 and -cdk2 antibodies were obtained from Santa Cruz Biotechnology, Inc. Monoclonal against 5′-bromo-2′-deoxyuridine (Brdu) was purchased from Dako. mAbs recognizing p21waf1/cip1 and pRb were purchased from BD PharMingen, mAbs anti-p27kip1 was obtained from BD Transduction Labs, and monoclonal anti–cyclin D1 was purchased from Sigma-Aldrich. Polyclonal and monoclonal PKCα-specific antibodies were purchased from Gibco BRL and Upstate Biotechnology, respectively. HRP-conjugated goat anti-rabbit IgG and donkey anti–IgG antibodies, and unconjugated anti-green fluorescent protein (GFP) mAbs were obtained from Boehringer. HRP-conjugated rat anti–mouse IgG, TRITC-conjugated donkey anti–rabbit IgG, and TRITC-conjugated goat anti–mouse IgG antibodies were purchased from Jackson Immunoresearch Laboratories. TRITC-conjugated donkey anti–goat IgG and unconjugated goat anti–mouse IgG were obtained from Accurate Chemical & Scientific Corp.

**Identification of Proliferating Crypt Cells In Situ**

To label proliferating intestinal epithelial cells in S phase, an aqueous solution of 120 mg/kg of the thymidine analogue BrdU (Sigma-Aldrich) was injected intraperitoneally into Sprague-Dawley (CD) rats (Charles River Laboratories) 2 h before killing. Paraffin sections of formalin-fixed duodenum were heated (95°C) in 10 mM citrate buffer, pH 6.0, for 20 min for antigen retrieval, blocked in PBS containing 0.03% casein and 0.05% Tween 20, and immunostained with anti-BrdU antibody (1:10 dilution), followed by unconjugated goat anti–mouse secondary antibody (1:100 dilution) and HRP-conjugated donkey anti–goat tertiary antibody (1:100 dilution). Bound peroxidase was detected by incubation in 0.1% diaminobenzidine and 0.01% H2O2, and sections were counterstained with Harris hematoxylin.

**Immunofluorescence Staining**

Duodenal tissue from 200-g male Sprague-Dawley (CD) rats (Charles River Laboratories) was removed and flushed with ice-cold PBS. Tissue used for p15, p16, cyclin D1, and cdk2 immunostaining was immediately frozen in liquid nitrogen–cooled 2-methylbutane. Sections (4-μm thick) were cut on a cryostat microtome (Reichert-Jung), thaw-mounted onto gelatin-coated slides, and fixed in 2% formaldehyde/PBS for 15 min. Tissue used for p21waf1/cip1, p27kip1, cdk4, cyclin A, cyclin E, p107, pRb, p130, and PKCα immunostaining was fixed immediately after removal in 2% freshly polymerized paraformaldehyde/PBS for 2 h at 4°C, washed three times (15 min) in 50 mM NH4Cl/PBS, cryoprotected in 30% sucrose/PBS for at least 1 h, and frozen as described above.

Non-specific binding of antibodies to tissue sections was blocked by pre-incubation in blocking buffer (PBS containing 0.03% casein and 0.05% Tween 20) for 30 min at room temperature. Sections were then immunostained essentially as described previously (Saxon et al., 1994). In brief, sections were incubated with primary antibody in PBS containing 0.2% Triton X-100 (Sigma-Aldrich) for 60 min, followed by a 15 min PBS/Triton wash, 40 min in secondary antibody in PBS/Triton, and a 15 min PBS wash. Primary antibody dilutions were 1:10 for anti–cyclin D1, 1:25 for anti-cdk2 and -p21waf1/cip1, 1:50 for anti-p27kip1, 1:100 for anti–PKCα, -p16, –cyclin A, –cyclin E, -p130, 1:200 for anti–cdk4, -p107, and -pRb, and 1:400 for anti-p15. TRITC-conjugated secondary antibodies were used at 1:100 dilution. Fluorescence was viewed with a ZEISS epifluorescence microscope equipped with the appropriate optics and filter modules.

**Cell Culture, PKC Activation Protocols, and Subcellular Fractionation**

The IEC-18 cell line (American Type Culture Collection), a nontransformed intestinal crypt cell line derived from rat ileal epithelium (Quaroni and May, 1980), was maintained in DME (GIBCO BRL) supplemented with 10 μg/ml insulin, 4 mM glutamine, and 5% FCS (Intergen). PKC isoforms were activated in these cells by treatment with a panel of PKC activators including 100 nM PMA (Sigma-Aldrich), 100 nM 12-deoxyphorbol 13-phenylacetate (dPP; Alexis Corp.), 58 μM 1,2-dioctanoyl-sn-glycerol (Dio; Sigma-Aldrich), 100 nM phorbol 12,13-dibutyrate (PDBu; Alexis Corp.), 200 nM 12-deoxyphorbol 13-phenylacetate 20-acetate (dPPA; Alexis Corp.), 20 nM thymeleatoxin (Thy; Alexis Corp.), or 10 μM resveratrol (Res; Alexis Corp.).
Construction of a Retroviral Vector for Expression of PKCα-GFP Fusion Protein in IEC-18 Cells

To generate a retroviral vector for expression of PKCα fused at its COOH terminus to the NH2-terminal end of GFP, PKCα cDNA (American Type Culture Collection) was excised from pBluecript with EcoRI and ligated into the EcoRI sites of EGFP-N1 (CLONTECH Laboratories, Inc.). After correct orientation of the cDNA was confirmed, the stop codon of PKCα was mutated to an alanine codon by PCR-based mutagenesis (Cormack, 1997), using the primers 5'-ATCTGTTGCAAGGAGCGTTG-3' and 3'-TTGATCCACGTCACTCTGTTAGAT-5' to introduce the mutation. Presence of the required alteration and absence of other PCR-induced mutations was confirmed by sequencing. The PKCα-GFP fusion cDNA was excised from this construct by consecutive digestion with NotI and EcoRI. Between these digestions, the NotI cut was blunt-ended using the Klenow fragment of DNA polymerase. The cDNA was ligated into the EcoRI and blunt-ended BamHI sites of pLXSN (CLONTECH Laboratories, Inc.). This process generated the pLXSN-PKα-GFP plasmid in which expression of PKCα-GFP fusion protein is under control of the Moloney murine leukemia virus long terminal repeat.

Transduction of IEC-18 Cells with PKCα-GFP

For packaging of retroviral particles, the Phoenix amphotropic cell line (American Type Culture Collection) was transfected with pLXSN or pLXSN-PKα-GFP using the calcium phosphate precipitation method (Chen and Okayama, 1987). Cells were exposed to precipitate for 12–18 h at 37°C. Cells were rinsed twice in DME, and returned to complete medium for 24 h. This process generated the pLXSN-PKα-GFP plasmid in which expression of PKCα-GFP fusion protein is under control of the Moloney murine leukemia virus long terminal repeat.

Flow Cytometric Analysis

Propidium iodide staining of cellular DNA was performed and quantified as described previously (Frey et al., 1997). Briefly, cells were fixed in 70% ethanol and treated with 0.04 mg/ml RNase A (Sigma-Aldrich) in 20 mM HEPES, pH 7.4, 100 mM NaCl, 10 mM MgCl2, 5 mM MnCl2, 10% glycerol, 0.5 mM Na3VO4, 50 mM NaF, 5 mM NaPPI, 10 mM Mg-β-glycerophosphate), combined with substrate (2 μg GST-pRb; Santa Cruz Biotechnology, Inc.) or 10 μg purified histone H1 (Upstate Biotechnology) and 10 μCi [γ-32P]ATP, and incubated for 20 min at 30°C. Reaction products were separated by SDS-PAGE and dried gels were exposed to x-ray film. Autoradiograms were analyzed using a densitometer and ImageQuant Software (Molecular Dynamics).

Selective Downregulation of PKCδ and -ε from IEC-18 cells

Subconfluent IEC-18 cells were treated with 100 nM PMA for 15 min, rinsed twice in DME, and returned to complete medium for 24 h. This procedure has previously been demonstrated to selectively downregulate PKCδ and -ε, producing a population of cells expressing PKCα as the major agonist-responsive PKC isoform (Frey et al., 1997).

Results

Previous results from this laboratory have established a strong link between PKC isoform signaling and control of cell growth/cell cycle progression in intestinal epithelial cells. Several members of the PKC family (α, βII, δ, ε, ζ, δ, and η) undergo marked changes in expression and membrane association, parameters indicative of PKC activation, precisely as cells cease division in the crypts of the small intestines.

Table I. PKC Agonists Produce Cell Cycle Arrest in IEC-18 Cells

| Condition | Gp/Gi | S | Gp/M |
|-----------|-------|---|------|
| Control   | 58    | 30 | 12   |
| PMA 100 nM| 69    | 8  | 23   |
| dPP 100 nM| 69    | 9  | 22   |
| dPPA 200 nM| 67  | 15 | 18   |
| Thy 20 nM | 68    | 10 | 22   |
| Res 10 μM | 67    | 10 | 23   |
| DiC6 58 μM| 65    | 15 | 20   |

Asynchronously growing IEC-18 cells were treated with PKC agonists for 6 h and subjected to flow cytometric analysis to determine cell cycle distribution. PKC activation resulted in a marked decrease in cells transiting through S phase.
tine and colon in situ (Fig. 1, a–c) (Saxon et al., 1994; Verstovsek et al., 1998). In addition, direct activation of PKC (α, δ, and ε) in the IEC-18 intestinal crypt cell line with a panel of PKC agonists, including phorbol esters (PMA, dPP, PDBu, dPPA, Thy, and Res) and the diacylglycerol analogue DiC₈, results in cell cycle arrest in G₀/G₁ (Table I and Fig. 1 d) (Frey et al., 1997). Depletion of phorbol ester–responsive PKC isozymes (α, δ, and ε) by long-term treatment with PDBu abrogates the growth-inhibitory effects of these agents, pointing to PKC as a major mediator of this response (Frey et al., 1997). Furthermore, the duration of the effect is directly related to the presence of membrane-associated/active PKC in the cells. Treatment of asynchronously growing IEC-18 cells with

Figure 1. Relationship between PKC signaling and growth arrest in intestinal epithelial cells. (a) Diagram of intestinal epithelial crypt–villus architecture, indicating the point of growth arrest/PKC activation in the midcrypt region and the crypt–villus junction. (b) Immunodetection of BrdU incorporation to identify proliferating cells in small intestinal crypts. Arrow indicates point of growth arrest. P, proliferation zone; D, differentiation zone; V, villus/functional zone; J, crypt–villus junction. (c) Immunofluorescence localization of PKCα in rat duodenum. PKCα is diffusely distributed throughout the cytosol of proliferating lower crypt cells (P). Coincident with growth arrest in the midcrypt region (cell position 14–18 from the crypt base; arrow), levels of PKCα markedly increase and the protein becomes clearly detectable at the cell periphery, in the classical indication of PKC activation. (d) IEC-18 cells were treated with 100 nM PMA for the indicated times (U, control), and DNA content/cell cycle distribution was determined by flow cytometric analysis. PMA-induced cell cycle arrest is held for ~12 h of treatment. (e) IEC-18 cells were treated with 100 nM PMA for 12 h and analyzed for expression of PKC isoforms by Western blot analysis. U, untreated. (f) Vector control (Vec) and PKCα-GFP–expressing IEC-18 cells were treated with 100 nM PMA for the indicated times, and cell cycle distribution was determined by flow cytometric analysis. Although vector control cells reenter S phase by 12–14 h, PKCα-GFP–expressing cells remain arrested until between 18 and 24 h. (g) Vector control and PKCα-GFP cells were treated with 100 nM PMA for 12 h and subjected to Western blot analysis using antibodies against PKCα and GFP. Note that, although endogenous PKCα is undetectable in vector-transduced cells at 12 h, PKCα-GFP–transduced cells still contain readily detectable, albeit diminished, levels of the fusion protein at this time point. Data are representative of at least four independent experiments (results of PKCα-GFP overexpression are representative of four separate transductions). Bar, 10 μm.
PMA, which initially activates but subsequently downregulates PKCα, -δ, and -ε in this system, results in a transient cell cycle blockade (Frey et al., 1997). To confirm the involvement of this isozyme in phorbol ester–induced cell cycle arrest, IEC-18 cells were retrovirally transduced to express a PKCα-GFP fusion protein, and effects of PMA on cell cycle progression and PKC expression were examined. Expression of PKCα-GFP significantly extended (~6 h longer) phorbol ester–induced cell cycle arrest in this system (Fig. 1 f), and this effect correlated with increased (two- to threefold) and prolonged expression of PKCα proteins in PKCα-GFP–transduced cells (Fig. 1 g). Expression of other PKC isozymes (δ, ε, ζ, and ω) was unaltered in PKCα-GFP–expressing cells, and phorbol ester–induced downregulation of PKCδ/ε followed the same kinetics as seen in vector control cells (data not shown). Taken together with our previous findings, these data directly support the involvement of member(s) of the PKC family, and of PKCα in particular, in induction and maintenance of cell growth/cell cycle arrest in intestinal epithelial cells.

To investigate further the mechanisms involved in PKC-mediated inhibition of cell cycle progression in intestinal epithelial cells, PKC-induced alterations in the expression and activity of critical cell cycle regulatory molecules were determined in IEC-18 cells. The physiological relevance of these changes was then evaluated by comparing the developmental regulation of PKC isozymes and cell cycle control molecules along the crypt–villus axis in the unperturbed intestinal epithelium in situ.

**Figure 2.** Altered expression and phosphorylation of the pocket proteins p107, pRb, and p130 after PKC activation in IEC-18 cells. IEC-18 cells were treated with 100 nM PMA for the indicated times (U, untreated), and expression and phosphorylation state of pocket proteins were determined by Western blot analysis. Altered phosphorylation of these molecules is reflected in characteristic changes in their migration patterns on SDS gels. p130 is detected as forms 1, 2, and 3; the accumulation of forms 1/2 after PMA treatment is a hallmark of cell cycle withdrawal into G0. Data are representative of at least three independent experiments.

**Figure 3.** Developmental regulation of pocket protein expression and phosphorylation state in the intestinal epithelium in situ. (a–c) Immunofluorescence localization of pocket proteins. P, proliferation zone; D, differentiation zone; V, villus/functional zone. (a) p107 is readily detected in the nuclei of proliferating lower crypt cells (P). Coincident with growth arrest (arrow), p107 expression decreases to barely detectable levels. (bi and bii) pRb staining is evident in both nuclear and cytosolic compartments of proliferating crypt cells (P), and becomes predominantly nuclear in postmitotic cells of the upper crypt and villus (V). The arrow indicates the point of growth arrest. (c) p130 staining is low in proliferating crypt cells (P), but increases markedly coincident with growth arrest (arrow). (d) Whole cell lysates (30 μg protein) of isolated crypt (C), lower villus (LV), and upper villus (UV) cells were subjected to Western blot analysis for expression and migration/phosphorylation state of pocket proteins. Note that the crypt fraction includes some postmitotic cells of the upper crypt region. p130 form 3, which is only found in cycling cells, is only detected in the crypt fraction; the presence of forms 1 and 2 in this fraction reflects the postmitotic cells in this sample. Data are representative of at least three independent experiments. Bar, 10 μm.
PKC Signaling Regulates Pocket Protein Expression and Phosphorylation State in Intestinal Epithelial Cells

To investigate the role of pocket proteins in PKC-mediated cell cycle arrest in IEC-18 cells, the effects of PKC activation on the expression and phosphorylation state of these molecules were determined using Western blot analysis. This analysis was based on well-documented evidence that alterations in phosphorylation state of pocket proteins are reflected in characteristic changes in their migration patterns on SDS-PAGE gels (Ludlow et al., 1990; DeCaprio et al., 1992; Whyte and Eisenman, 1992; Garriga et al., 1998; Smith et al., 1998; Thomas et al., 1998). As shown in Fig. 2, proliferating (untreated) IEC-18 cells express p107, pRb, and small amounts of p130; p107 and pRb are detected primarily in their hyperphosphorylated (i.e., slower-migrating), growth-permissive forms. Treatment with 100 nM PMA resulted in decreased expression and hypophosphorylation (i.e., appearance of characteristic faster-migrating forms) of p107 and pRb, and a marked accumulation of the faster-migrating forms 1/2 of p130 (which is characteristic of cell cycle exit into G0; see Mayol et al., 1995). These PMA-induced alterations were transient, reversing by 12–16 h after addition of agonist, coincident with release from cell cycle arrest as a consequence of PKC downregulation (see Fig. 1, d and e).

To examine the physiological relevance of these data, a combined biochemical and morphological approach (described previously in Saxon et al., 1994) was used to compare the developmental regulation of pocket protein expression, subcellular distribution, and phosphorylation state along the crypt–villus axis in situ with changes in PKC activation/expression. Immunofluorescence analysis revealed that p107, pRb, and low levels of p130 are expressed in proliferating crypt cells (Fig. 3, a–c); p107 staining was predominantly nuclear, whereas pRb staining was detected both in the cytoplasm and the nucleus. Coincident with cell growth arrest and PKC activation in the midcrypt region (cell position 14–18 from the crypt base; Fig. 1, b and c), all three pocket proteins underwent changes in expression and/or subcellular compartmental-
noprecipitates from untreated cells (Fig. 4), and the activity in both complexes was markedly inhibited after PMA treatment. Cyclin E–associated activity was decreased by 46% at 2 h and by 73% at 6 h. By 8 h, although still inhibited by 48%, cyclin E–cdk2 activity was beginning to rebound. Cyclin A–associated activity was decreased by 55% within 2 h of treatment, and was below the accurate detection limit of the assay at 6 and 8 h (see Fig. 5).

**Effects of PKC Activation on Cyclin–Cdk Expression Levels in Intestinal Epithelial Cells**

Cdk activity can be affected by three major factors: expression of cdk4 and cyclins, positive and negative phosphorylation events, and association with CKIs (Chellappan et al., 1998; Sherr and Roberts, 1999). To determine whether changes in expression or phosphorylation of cdk4 or cyclins could account for PKC-mediated inhibition of cdk activity in IEC-18 cells, Western blot analysis of whole cell lysates from control and PMA-treated IEC-18 cells was performed. As shown in Fig. 5, no detectable changes were observed in the expression or electrophoretic mobility (phosphorylation state) of cdk4 and 2 in IEC-18 cells over the course of PMA treatment. In contrast, alterations in cyclin expression were observed after PKC activation in IEC-18 cells. The most rapid changes were seen with the D-type cyclins. As shown in Fig. 5, exposure to 100 nM PMA consistently resulted in depletion of cyclin D/D1 by

![Figure 5](image)

*Figure 5. Effect of PMA treatment on the expression of cyclins and cdk4 in IEC-18 cells. Cells were exposed to 100 nM PMA for the indicated times (U, untreated) and subjected to Western blot analysis using antibodies specific for cdk4, cdk2, and cyclins D (pan), D1, E, and A. Data are representative of three independent experiments.*

![Figure 6](image)

*Figure 6. Analysis of the developmental regulation of cdk and cyclin expression in the small intestinal epithelium. Immunofluorescence analysis of (a) cdk4, (b) cdk2, (c) cyclin E, and (d) cyclin A expression was performed on rat duodenal tissue. All four molecules are readily detectable in crypt cells (C), and undergo a marked decrease in expression at the crypt–villus junction (J), well beyond the point of growth arrest (arrow). Note the variable expression of cyclin A in proliferating cells (d, inset). P, proliferation zone; D, differentiation zone; V, villus. (e) Western blot analysis of cdk and cyclin expression in isolated crypt (C), lower villus (LV), and upper villus (UV) cell populations. Data are representative of at least three independent experiments. Bar, 10 𝜇m.*
PKC Signaling Regulates the Expression of Cip/Kip but Not Ink4 Family CKIs in Intestinal Epithelial Cells

Previous studies in this laboratory have demonstrated that PKC agonist treatment of IEC-18 cells results in induction of the Cip/Kip CKIs p21<sup>waf1/cip1</sup> and p27<sup>kip1</sup>. This report extends these findings by (a) examining the extent and time course of p21<sup>waf1/cip1</sup> and p27<sup>kip1</sup> induction, (b) determining the association of p21<sup>waf1/cip1</sup> and p27<sup>kip1</sup> with cyclin–cdk complexes, and (c) expanding the analysis to include the Ink4 family members. As shown in Fig. 7 a, a substantial accumulation of p21<sup>waf1/cip1</sup> was observed in IEC-18 cells by 2 h of PKC agonist treatment, with levels remaining elevated for 6 h and returning to baseline by 12 h. The increased expression of p27<sup>kip1</sup> exhibited delayed kinetics relative to p21<sup>waf1/cip1</sup> induction, with peak levels sustained between 6 and 12 h of PKC agonist treatment. (It should be noted that the level of induction of p27<sup>kip1</sup> exhibited some variability at early time points, but was consistently high at later times.) In contrast to the Cip/Kip CKIs, the Ink4 CKIs p15 and p16 were not observed in either proliferating or PMA-arrested IEC-18 cells. Thus, PKC-mediated intestinal epithelial cell cycle arrest appears to involve specific induction of Cip/Kip CKIs, and does not require participation of Ink4 family members (Fig. 7 a).

To determine if PKC activation in IEC-18 cells resulted in increased association of Cip/Kip CKIs with cyclin–cdk complexes, immunoprecipitates were prepared from control and PKA-treated cells using antibodies directed against cyclin D, cyclin E, or cyclin A, and immunocomplexes were analyzed for the presence of p21<sup>waf1/cip1</sup> and p27<sup>kip1</sup> by Western blotting. Markedly increased levels of CKIs were detected in cyclin E and cyclin A immunocomplexes by 2 h (Fig. 7 b). CKI levels in cyclin E complexes peaked at 6 h and began to decline by 8 h, whereas those in cyclin A complexes decreased sharply by 6 h, paralleling the loss of cyclin A expression at this time point (see Fig. 5). Increased association of p21<sup>waf1/cip1</sup> and p27<sup>kip1</sup> with cyclin D was not observed at early times after addition of PKA, presumably reflecting the initial downregulation of the weak signal produced by pan-D and anti-cyclin D1 antibodies in this tissue. Cdks 4 and 2 and cyclins E and A were all detected in the nuclei of proliferating intestinal crypt cells (Fig. 6 a–d). Levels of cyclin A expression varied from cell to cell, presumably reflecting different stages of the cell cycle (Fig. 6 d). Notably, major changes in the expression of these cyclins and cdks were observed only at the crypt–villus junction, well beyond the point of growth arrest and PKC activation in the midcrypt region. As cells exited the crypts, expression of cdks 4 and 2 and cyclins E and A decreased markedly, although low levels of these molecules remained detectable along the length of the villus. The regulation of cyclin and cdk expression in proliferating, differentiating, and functional intestinal epithelial cells was confirmed by Western blot analysis of isolated cell populations (Fig. 6 e). Together, these data suggest that decreased expression of cdks 4 and 2 and cyclins E and A in intestinal tissue is a downstream consequence rather than a cause of the accumulation of cells in G<sub>0</sub>/G<sub>1</sub>, and that the loss of cyclin E– and A–associated cdk activity observed shortly after PKA treatment of IEC-18 cells is not due to limited cyclin or cdk availability.
D-type cyclins resulting from this treatment (see Fig. 5). However, significantly elevated levels of CKIs were seen in cyclin D complexes at later times, paralleling the resurgence of cyclin D seen with PKC downregulation. Interestingly, high levels of CKI recruitment to cyclin D immunocomplexes at 8 h were coincident with decreased association of p21waf1/cip1 and p27kip1 with cyclins E and A and restoration of cyclin E–cdk2 activity. The sequestration of these CKIs by cyclin D–cdk4/6 complexes has been suggested by some investigators to be a mechanism for relief of cdk2 inhibition, contributing to orderly progression through late G1 phase (Geng et al., 1999; Roberts, 1999).

Immunofluorescence analysis revealed that PKC-mediated control of CKI expression in IEC-18 cells parallels CKI regulation along the crypt–villus axis in situ. Relatively low levels of p21waf1/cip1 were observed in the nuclei of proliferating lower crypt cells, whereas p27kip1 was undetectable in these cells (Fig. 8, a and b). Coincident with growth arrest, upregulation/activation of PKC, and alterations in pocket protein expression/phosphorylation, levels of both Cip/Kip CKIs increased markedly. Upregulation of p21waf1/cip1 was transient; expression remained high in the actively differentiating cells of the upper crypt and lower villus and decreased to barely detectable levels in functional cells of the villus tip. In contrast, changes in p15 and p16 expression did not correlate with growth arrest and PKC activation in the midcrypt region (Fig. 8, c and d). Moderate levels of p15 and low amounts of p16 were detected in cells throughout the entire crypt. Increased p15 expression became apparent at the crypt–villus junction, which is well into the postmitotic compartment (Fig. 8 c), and levels of this molecule remained high along the length of the villus.
Levels of p16, on the other hand, increased gradually with cell migration up the villus (Fig. 8 d). These patterns of Cip/Kip and Ink4 family CKI regulation along the crypt–villus unit were consistent with those observed by Western blot analysis of isolated crypt, lower villus, and upper villus cells (Fig. 8 e). Thus, upregulation of p21waf1/cip1 and p27kip1 expression in the midcrypt region coincides precisely with changes in PKC expression/activation, alterations in pocket protein expression/phosphorylation, and growth arrest. Changes in p15 and p16 do not correlate with PKC activation in this system.

**PKC Activation in IEC-18 Cells Results in Downregulation of the DNA Licensing Factor Cdc6**

The depletion of D-type cyclins and coordinated alterations in pocket protein expression/phosphorylation observed after PMA treatment of IEC-18 cells suggested that PKC activation in this system signals cell cycle withdrawal into G0. To further investigate this possibility, control and PMA-treated IEC-18 cells were analyzed for expression of the cdc6 DNA licensing factor, a molecule that is strictly associated with actively cycling populations and whose downregulation is indicative of cell cycle exit (Stillman, 1996; Fujita, 1999). PKC activation in IEC-18 cells resulted in marked downregulation of cdc6 by 2 h of treatment (Fig. 9), confirming cell cycle withdrawal into G0 or a G0-like state. Levels of this molecule recovered by 10–16 h, reflecting downregulation of PKC isozymes and reentry of IEC-18 cells into the cell cycle.

**PKCα Is Sufficient to Initiate a Program of Cell Cycle Withdrawal in IEC-18 Cells**

Work from this and other laboratories has linked PKCα, in particular, to negative control of intestinal epithelial cell growth (Frey et al., 1997; Abraham et al., 1998; Scaglione-Sewell et al., 1998; also see Fig. 1). To investigate the ability of approximately physiological levels of this isozyme to signal cell cycle exit in intestinal epithelial cells, a population of IEC-18 cells expressing PKCα but not other phorbol ester–responsive isozymes was prepared by brief exposure to PMA as described in Materials and Methods (Fig. 10 a) (Frey et al., 1997). We have previously shown that activation of PKCα in this population by a second application of PMA is sufficient to induce cell cycle arrest (Frey et al., 1997). As shown in Fig. 10 b, treatment of these PKCα-expressing cells (P) with 100 nM PMA for 2 h (R) resulted in hypophosphorylation and downregulation of p107 and pRb, accumulation of forms 1/2 of p130, loss of cyclin D, induction of p21waf1/cip1, and decreased expression of cdc6. Thus, PKCα activation alone is sufficient to recapitulate the conserved program of changes in CKIs, cyclins, and pocket proteins indicative of cell cycle withdrawal into G0 or a G0-like state. The observed responses were generally of slightly lesser magnitude than in control cells expressing the full profile of PMA-responsive isozymes, likely reflecting the slightly decreased amounts of PKCα remaining after PMA pulse treatment (Fig. 10 a).

**Discussion**

Through coordinate analysis of in vitro and in situ model systems, this study investigates the mechanisms by which PKC regulates cell cycle progression in intestinal epithelial cells. The data demonstrate for the first time that PKC activation can initiate a specific program of molecular events associated with cell cycle withdrawal into G0 or a G0-like state. Treatment of IEC-18 intestinal crypt cells with PKC agonists resulted in rapid downregulation of D-type cyclins, rapid and transient induction of p21waf1/cip1, delayed but sustained accumulation of p27kip1, inhibition of cyclin E– and cyclin A–associated kinase activity, coordinated alterations in pocket protein expression and phosphorylation, and downregulation of the DNA licensing factor cdc6. Manipulation of PKC isozyme levels in IEC-18 cells demonstrated that PKCα, in particular, is sufficient to produce this program of negative growth regulatory events. Furthermore, comparison of the developmental regulation of PKC isozymes and cell cycle control molecules in intestinal epithelial tissue revealed that (a) the program of events triggered by PKC activation in IEC-18 cells is representative of the changes seen in cell cycle regulation coincident with growth arrest in situ, and (b) PKC activation is appropriately positioned within intestinal crypts to initiate this program of cell cycle exit–associated events in situ.

**PKC Activation in Intestinal Epithelial Cells Results in Coordinated Changes in Pocket Protein Expression and Phosphorylation**

Data obtained from studies in multiple systems suggest a model for control of cell cycle exit which involves both alterations in pocket protein phosphorylation state and an orchestrated shift in relative levels of these molecules (Moberg et al., 1996; Smith et al., 1996; Mayol and Graña, 1998). In this model, proliferating cells primarily express p107 and pRb as regulators of E2F function and thus G1/S progression; p130 is present at low levels in cycling cells. Cell cycle exit and differentiation are associated with hypophosphorylation of p107 and pRb, disappearance of p107 (and, in some systems, decreased expression of pRb), and marked accumulation of phosphoforms 1 and 2 of p130. p130 forms 1/2 are maintained in G0 cells as long-term binding partners and repressors of E2F-4. This program of pocket protein regulation has been shown to occur during in vitro skeletal muscle myogenesis (Garriga et al., 1998), granulocytic differentiation of mouse myeloid precursor cells (Garriga et al., 1998), and IFN-α–induced cell cycle exit of Daudi B cells (Thomas et al., 1998). Furthermore, similar patterns of pocket protein expression have been observed during epidermal differentiation in situ (Paramio et al., 1998).
Figure 10. PKCa activation is sufficient to initiate cell cycle withdrawal in IEC-18 cells. (a) IEC-18 cells were pulsed with PMA for 15 min to selectively downregulate PKCδ and -ε, and PKC isozyme expression was determined by Western blot analysis. (b) PKCδ- and -ε-depleted cells were re-treated with PMA for 2 h and analyzed by Western blotting for expression and migration/phosphorylation state of cell cycle regulatory molecules. U, untreated; P, phorbol ester–pulsed cells expressing PKCa but not -δ or -ε; R, PKCa-expressing cells retreated with PMA. Data are representative of three independent experiments. (c) Model of PKCa-mediated intestinal epithelial cell cycle withdrawal (see text for details). (d) Time line of events involved in PKC-mediated cell cycle exit in IEC-18 cells.
In striking parallel to these findings, the data presented in the current study show that PKC-induced inhibition of cell cycle progression in IEC-18 cells is associated with hypo-phosphorylation and downregulation of p107 and pRb and with coordinated upregulation of p130 forms 1/2 (see Fig. 2). Although previous work in other systems has linked PKC to regulation of the function of pRb (for reviews see Fishman et al., 1998; Black, 2000), the data presented here are the first to implicate PKC signaling in coordinated regulation of the expression and phosphorylation state of all three members of the pocket protein family. The ability of PKC signaling to induce this program of pocket protein control in IEC-18 cells points to a role for member(s) of this family in signaling cell cycle withdrawal in intestinal epithelial cells. This notion is strengthened by the finding that PKC activation within intestinal crypts in situ coincides precisely with similar changes in pocket protein regulation, i.e., decreased pocket protein phosphorylation, downregulation of p107, decreased expression and restriction of pRb to the nucleus, and increased expression of p130 (see Figs. 1 and 3). The disappearance of pRb from the cytoplasm of post-mitotic cells (Fig. 3b) (Chandrasekaran et al., 1996) suggests an additional mechanism of pocket protein regulation; however, the role of pocket protein subcellular distribution in regulating E2F function remains to be determined.

**PKC Signaling Inhibits Cyclin–Cdk Activity in Intestinal Epithelial Cells**

Inhibition of cyclin–cdk complex activity is critical for activation of pocket protein growth-suppressive function and cell cycle exit (Graña and Reddy, 1995). PKC activation in IEC-18 cells appears to negatively regulate the function of all major cyclin–cdk complexes involved in G0/G1→S progression, i.e., cyclin D–cdk4/6, cyclin E–cdk2, and cyclin A–cdk2. Regulation of cyclin–cdk complexes by PKC signaling appears to involve two distinct mechanisms: changes in cyclin expression (modulating cyclin D complexes) and accumulation of CKIs (targeting cyclin E– and cyclin A–associated activity).

PKC activation in IEC-18 cells resulted in rapid disappearance of D-type cyclins, presumably leading to loss of any cdk4/6 activity present in these cells. Although delayed expression of cyclin D has been observed after growth factor stimulation of quiescent PKC-overexpressing cells in other systems (Fukumoto et al., 1997; Ashton et al., 1999), to our knowledge this study is the first to demonstrate the ability of PKC signaling to mediate the downregulation of this molecule in actively cycling cells. Several lines of evidence exclude a role for CKI accumulation in PKC-mediated modulation of cyclin D–associated activity. First, PKC has not been linked to induction of the cyclin D–cdk4/6-specific CKIs p15 or p16 in any system (Black, 2000), including IEC-18 cells (see Fig. 7a), and PKC activation in intestinal crypts in situ does not coincide with increased expression of either of these CKIs (see Fig. 8). Furthermore, recent evidence suggests that the Cip/Kip CKIs p21waf1/cip1 and p27kip1 are inefficient inhibitors of cyclin D–associated cdk activity (LaBaer et al., 1997), a notion supported by a study of Caco-2 colon adenocarcinoma cell differentiation in which association with p21waf1/cip1 was shown to be a critical component of cdk2 but not cdk4 inhibition (Ding et al., 1998). Together these data support a role for downregulation of D-type cyclins, rather than CKI association, in regulation of cdk4/6 activity by PKC-mediated signaling. Since levels of cyclin D remain relatively constant throughout the cell cycle in cycling cells and destruction of this molecule has been shown to be an early event in cell cycle withdrawal into G0 (Zwijsen et al., 1996), these data provide additional evidence for the ability of PKC signaling to induce a G0-like state in this system. The resurgence of cyclin D in IEC-18 cells after downregulation of PKC isozymes likely reflects reversal of cell cycle withdrawal and reentry of these cells from G0 into G1; similar hyperinduction of this molecule has been reported during serum-stimulated cell cycle entry from quiescence in several systems (e.g., Coppock et al., 1995; Fukumoto et al., 1997).

Inhibition of cdk2 complexes by PKC activation in IEC-18 cells appears to be accomplished through CKI binding rather than by destruction of cyclins. In this regard, cyclin E and cyclin A levels remained unchanged at times when their associated cdk activity was significantly inhibited (see Figs. 4 and 5). Downregulation of cyclin A was only observed at later time points (6 and 12 h), likely as a consequence of PKC-induced accumulation of cells in G1/G0 (cell cycle stages at which cyclin A is not normally expressed; Graña and Reddy, 1995). These findings are consistent with data from other systems demonstrating PKC-induced inhibition of cdk2 activity under conditions in which levels of cyclins E or A were not limiting (Coppock et al., 1995; Livneh et al., 1996; Ashton et al., 1999). The notion that intestinal epithelial cell cycle withdrawal does not require the destruction of cyclins E and/or A was confirmed by the observation that, in intestinal tissue, downregulation of these molecules occurs at the crypt–villus junction, well after growth arrest in the midcrypt region (see Fig. 6). Although PKC activation in IEC-18 cells did not result in early alterations in cyclin E or A expression, increased levels of Cip/Kip CKIs were detected in both cyclin E and A complexes soon after PMA treatment, and could thus account for the observed inhibition of their associated kinase activity. The finding that p21waf1/cip1 and p27kip1 induction in the midcrypt region in situ coincides precisely with PKC activation (see Figs. 8 and 1a) is consistent with this idea. A link between PKC signaling and increased Cip/Kip CKI expression has also been observed in a variety of other systems, including various epithelial cell types, leukemic cells, and cell lines overexpressing specific PKC isozymes (for review see Black, 2000). Together with the absence of evidence for direct effects of PKC activation on cyclin or cdk expression or phosphorylation, these data suggest that increased association with Cip/Kip CKIs is the major mechanism for inhibition of cyclin E– and cyclin A–associated cdk activity by PKC signaling in intestinal epithelial cells.

**PKC Signaling Differentially Regulates Cip/Kip CKI Expression in Intestinal Epithelial Cells**

Although PKC signaling resulted in increased expression of both p21waf1/cip1 and p27kip1 in IEC-18 cells, marked differences were observed in the kinetics of induction of these molecules. Levels of p21waf1/cip1 peaked early after PMA treatment and rapidly returned to those seen in control cells. In contrast, induction of p27kip1 peaked later and increased levels were sustained as long as the cells remained in G0. Consistent with these results, PKC-medi-
iated transient induction of p21waf1/cip1 has been noted in venous endothelial cells (Zezula et al., 1997), leukemic cell lines (Asiedu et al., 1995), and keratinocytes (Todd and Reynolds, 1998), and sustained induction of p27kip1 has been observed during PMA-induced hematopoietic differentiation (Asiedu et al., 1997). Notably, these findings parallel the developmental regulation of Cip/Kip CKIs along the crypt–villus axis in situ. Although p21waf1/cip1 and p27kip1 are both upregulated coincident with growth arrest within intestinal crypts, elevated levels of p21waf1/cip1 are present only during early stages of differentiation (Fig. 8) (Gartel et al., 1996), whereas p27kip1 expression is sustained along the length of the villus. Similarly, increased p21waf1/cip1 expression was detected only during early stages of maturation of conditionally immortalized human fetal intestinal cells in vitro, whereas p27kip1 induction was delayed and sustained, coinciding with the appearance of morphological and functional markers of differentiation (Tian and Quaroni, 1999). Recent findings suggest that the differential kinetics of induction of Cip/Kip CKIs reflect distinct roles for these molecules in the differentiation process, with p21waf1/cip1 playing a part in initiating irreversible growth arrest and p27kip1 functioning later to induce or maintain tissue-specific gene expression (Tian and Quaroni, 1999; Yamamoto et al., 1999). Evidence that p21waf1/cip1 expression may in fact play an inhibitory role during late stages of differentiation (Di Cunto et al., 1998; Yamamoto et al., 1999) suggests that its downregulation is required for completion of the maturation process. Taken together, these findings demonstrate that PKC signaling can regulate Cip/Kip family CKI expression in a manner consistent with that seen in association with cell cycle exit and differentiation in a variety of biological systems.

**PKCo Signals Cell Cycle Exit in Intestinal Epithelial Cells**

To determine the specific PKC isozyme(s) involved in signaling cell cycle exit in intestinal epithelial cells, we took advantage of our previous finding that brief exposure to PMA, followed by extended incubation in the absence of drug, generates a population of IEC-18 cells expressing PKCo but not other phorbol ester–responsive isozymes (Frey et al., 1997). Activation of PKCo in these cells produced the same program of cell cycle exit–associated events observed after PKC agonist treatment of IEC-18 cells expressing the full panel of PKC isozymes. These data are consistent with the ability of PKCo to mediate cell cycle arrest and differentiation in a variety of in vitro systems (Gruber et al., 1992; Mischak et al., 1993; Murray et al., 1993; Abraham et al., 1998; Scaglione-Sewell et al., 1998; Desai et al., 1999; Slosberg et al., 1999), with the demonstration that PKCo overexpression can potentiate phorbol ester–mediated growth arrest in mammary (Slosberg et al., 1999) and intestinal epithelial cells (see Fig. 1), and with the observation that activation of this isozyme is maintained in all postmitotic cells of the intestinal epithelium in situ (Saxon et al., 1994) (see Fig. 1 a). These findings strongly support the involvement of PKCo, in particular, in mediating a program of cell cycle withdrawal, although it remains to be determined whether other members of the PKC family play a role in this process. For example, it is possible that downregulation of PKCe, which has been implicated in positive regulation of cell growth (e.g., Cacace et al., 1993), is also required for execution of this program. The continued proliferation of cells depleted of PKCo, -δ, and -ε, however, indicates that PKCe downregulation in the absence of active PKCo is not sufficient to produce growth arrest of these cells.

In summary, the data presented herein indicate that PKC signaling plays an important role in initiating a coordinated program of cell cycle exit in intestinal epithelial cells and suggest a model of PKC-mediated cell cycle exit (summarized in Fig. 10, c and d). In this model, PKCo activation in IEC-18 cells leads to inhibition of G1/S cyclin–cdk activity via two distinct mechanisms: downregulation of D-type cyclins, which inhibits cdk4/6 activity, and accumulation of p21waf1/cip1 and p27kip1, which leads to inhibition of cyclin E– and cyclin A–associated cdk2. These effects result in hypophosphorylation/downregulation of p107 and pRb and accumulation of p130 forms 1/2, events which drive cells to exit the cell cycle into G0, as indicated by concomitant downregulation of cdc6. Sustained expression of p27kip1 and upregulation of p130 suggest that PKC-mediated cell cycle withdrawal is linked to the onset of a differentiation program. Analysis of the developmental regulation of pocket proteins, cyclins, cdk5, and CKIs in intestinal epithelial tissue demonstrates that the program of cell cycle–specific events resulting from PKC activation in cultured cells closely parallels the changes seen coincident with PKC activation/growth arrest in the midcrypt region in situ. We also propose that sustained activation of PKC is required for maintenance of cell cycle exit in this system. As PKCo is downregulated from phorbol ester–treated IEC-18 cells, cyclin D is reexpressed and accumulates to high levels (see Fig. 5), sequestering Cip/Kip CKIs (see Fig. 7) to promote assembly of cyclin D–cdk4/6 complexes (Roberts, 1999). Sequestration of p21waf1/cip1 and p27kip1 in cyclin D complexes, combined with decreased expression of p21waf1/cip1 (see Fig. 7), relieves inhibition of cdk2 (Roberts, 1999) (see Fig. 4), allowing inactivation of pocket proteins and progression through the cell cycle.

The physiological importance of PKC-mediated negative control of cell cycle progression is underscored by evidence of decreased PKC expression or activity in colonic tumors (Guillem et al., 1987; Wali et al., 1991; Kahl-Rainer et al., 1996; Verstovsek et al., 1998), by the ability of phorbol ester treatment to inhibit growth in normal colonic tissue from biopsies (Assert et al., 1999), and by evidence that certain PKC isozymes can act as tumor suppressors in intestinal epithelial cells (Choi et al., 1990; Abraham et al., 1998; Scaglione-Sewell et al., 1998). Since PKC activation and/or overexpression have been shown to inhibit cell growth/cell cycle progression in a variety of systems, the results presented in this study may represent a conserved growth-inhibitory function for one or more members of the PKC family.

We wish to thank Deborah Ogden, Sulochana Dave, and Mary Vaughan for expert assistance with the immunofluorescence and immunohistochemistry studies.

This work was supported by a grant from the Crohn’s and Colitis Foundation of America, by National Institutes of Health grants DK54909 and CA16056, by a grant from the Roswell Park Alliance Foundation, and by Developmental Funds from National Institutes of Health grant CA16056.

Submitted: 12 June 2000
Revised: 21 September 2000
Accepted: 25 September 2000
Abraham, C., B. Scaglione-Sewell, S.F. Skarosi, W. Qin, M. Bissonnette, and A.L. Tyner. 1996. p21 (WAF1/CIP1) expression is induced in newly nondiabetic pancreatic beta cells. Cell. 108:1436–1449.

Avery, J., S. Godycki, R. Schrier, and D.M. Livingston. 1996. p21 (WAF1/CIP1) expression is induced in newly nondiabetic pancreatic beta cells. Cell. 108:1436–1449.

Avery, J., S. Godycki, R. Schrier, and D.M. Livingston. 1996. p21 (WAF1/CIP1) expression is induced in newly nondiabetic pancreatic beta cells. Cell. 108:1436–1449.

Avery, J., S. Godycki, R. Schrier, and D.M. Livingston. 1996. p21 (WAF1/CIP1) expression is induced in newly nondiabetic pancreatic beta cells. Cell. 108:1436–1449.

Avery, J., S. Godycki, R. Schrier, and D.M. Livingston. 1996. p21 (WAF1/CIP1) expression is induced in newly nondiabetic pancreatic beta cells. Cell. 108:1436–1449.
p107, and pRb are differentially regulated in proliferating cells and during cell cycle arrest by alpha-interferon. *J. Biol. Chem.* 273:23659–23667.

Tian, J.Q., and A. Quaroni. 1999. Involvement of p21(WAF1/Cip1) and p27(Kip1) in intestinal epithelial cell differentiation. *Am. J. Physiol.* 276: C1245–C1258.

Todd, C., and N.J. Reynolds. 1998. Up-regulation of p21waf1 by phorbol ester and calcium in human keratinocytes through a protein kinase C-dependent pathway. *Am. J. Pathol.* 153:39–45.

Verstovsek, G., A. Byrd, N.J. Petrelli, and J.D. Black. 1998. Colonocyte differentiation is associated with increased expression and altered distribution of protein kinase C isozymes. *Gastroenterology.* 115:75–85.

Walt, R.K., C.L. Baum, M.J. Bolt, P.K. Dudeja, M.D. Sitrin, and T.A. Brasitus. 1991. Down-regulation of protein kinase C activity in 1,2-dimethylhydrazine-induced rat colonic tumors. *Biochim. Biophys. Acta.* 1092:119–123.

Weiser, M.M. 1973. Intestinal epithelial cell surface membrane glycoprotein synthesis. I. An indicator of cellular differentiation. *J. Biol. Chem.* 248:2536–2541.

Whyte, P., and R.N. Eisenman. 1992. Dephosphorylation of the retinoblastoma protein during differentiation of HL60 cells. *Biochem. Cell Biol.* 70:1380–1384.

Yamamoto, H., J.W. Soh, H. Shirin, W.Q. Xing, J.T. Lim, Y. Yao, E. Slosberg, N. Tomita, I. Schieren, and I.B. Weinstein. 1999. Comparative effects of overexpression of p21<sup>Cip1</sup> and p21<sup>WAF1/CIP1</sup> on growth and differentiation in human colon carcinoma cells. *Oncogene.* 18:103–115.

Zezula, J., V. Sexl, C. Hutter, A. Karel, W. Schutz, and M. Freissmuth. 1997. The cyclin-dependent kinase inhibitor p21<sup>Cip1</sup> mediates the growth inhibitory effect of phorbol esters in human venous endothelial cells. *J. Biol. Chem.* 272:29967–29974.

Zwijnsen, R.M., R. Klompmaker, E.B. Wientjens, P.M. Kristel, B. van der Burg, and R.J. Michalides. 1996. Cyclin D1 triggers autonomous growth of breast cancer cells by governing cell cycle exit. *Mol. Cell. Biol.* 16:2554–2560.